Tobramycin inhalation powder: A review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis

Drugs

Volumn 73, Issue 16, 2013, Pages 1815-1827

  McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; MUCOLYTIC AGENT; PLACEBO; SODIUM CHLORIDE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BRONCHOSPASM; COUGHING; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SPUTUM LEVEL; DRUG USE; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSGEUSIA; DYSPHONIA; DYSURIA; FEVER; FORCED EXPIRATORY VOLUME; HEARING IMPAIRMENT; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LUNG DISEASE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEPHROLITHIASIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHENOTYPE; POLYURIA; PROTEINURIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SORE THROAT; SPIROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; POWDERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 84889000280     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0141-0     Document Type: Review

References (47)

1. TM: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med. 2011;5(5):609-22.
2. VanDevanter DR, Geller DE. Tobramycin administered by the TOBI Podhaler for persons with cystic fibrosis: a review. Med Devices (Auckl). 2011. doi: 10.2147/MDER.S16360.
3. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7:450-3.
4. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011;9:32.
5. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-69.
6. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009;54(5):658-69.
7. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-51.
8. ®): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003;63:2501-20.
9. Sawicki GS, Sellers DE, Robinson WM, et al. High treatment burden in adults with cystic fibrosis: challenges to disease self management. J Cyst Fibros. 2009;8(2):91-6.
10. European Medicines Agency. TOBI Podhaler 28 mg inhalation powder, hard capsules. Summary of product characteristics. 2011. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002155/WC500110921. pdf. Accessed 17 Oct 2013.
11. Novartis Pharmaceuticals Corporation. TOBI PODHALER (Tobramycin Inhalation Powder). Full prescribing information. 2013. http://www.pharma.us. novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/tobipodhaler.pdf. Accessed 17 Oct 2013.
12. Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros. 2009;8(6):361-9.
13. Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros. 2012;11(4):293-9.
14. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
15. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8(5):295-315.
16. TM technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175-82.
17. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124(1):360-6.
18. Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19(4):456-65.
19. Geller D, Ament B, Heuerding S, et al. Inspiratory flow characteristics of the T-326 dry powder inhaler (DPI) in CF patients [abstract no. 72]. J Cyst Fibros. 2013;12(Suppl):S66.
20. ™) using inspiratory flow profiles from cystic fibrosis patients [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17-19 Oct 2013; Salt Lake City.
21. Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42(4):307-13.
22. Nasr S, Nick J, Ezzet N, et al. Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17-19 Oct 2013; Salt Lake City.
23. Ruddy J, Emerson J, Moss R, et al. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. J Aerosol Med Pulm Drug Deliv. 2013;26(2):69-75.
24. Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin. 2013;29(8):947-56.
25. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol. 2011;46(3):230-8.
26. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011;10(1):54-61.
27. Konstan MW, Flume PA, Wan R, et al. Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa: the EDIT trial and its two open-label extension studies [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17-19 Oct 2013; Salt Lake City.
28. Regnault A, Balp M-M, Kulich K, et al. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis. J Cyst Fibros. 2012;11(6):494-501.
29. Regnault A, Bal MM, Kulich K, et al. Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study. 34th European Cystic Fibrosis Conference; 8-11 June 2011, Hamburg.
30. Geller DE, Nasr SZ, Piggott S, et al. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care. 2013. doi: 10.4187/respcare.02264.
31. Harrison MJ, McCarthy C, Fleming C, et al. Improved tolerability, adherence and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulised antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS) [abstract no. 74]. J Cyst Fibros. 2013;12(Suppl):S67.
32. Nash EF, Ahitan B, Brown CJ, et al. Comparison of pharmacy prescription refill frequency in CF adults before and after switching from tobramycin inhalation solution (TIS) to TOBI Podhaler: 'real world' evidence of improved adherence [abstract no. 68]. J Cyst Fibros. 2013;12(Suppl):S65.
33. National Institute for Health and Clinical Excellence (NICE). Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. 2013 Mar. http://guidance.nice. org.uk/TA276/Guidance/pdf/English. Accessed 19 Aug 2013.
34. Cystic Fibrosis Foundation. Patient registry: annual data report. 2011. http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/. Accessed 21 Aug 2013.
35. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004;3:67-91.
36. Littlewood KJ, Higashi K, Jansen JP, et al. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J Cyst Fibros. 2012;11(5):419-26.
37. Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol. 2012;47(1):44-52.
38. Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38(4):314-20.
39. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121(1):55-63.
40. 1 in cystic fibrosis. Pediatr Pulmonol. 2013;. doi: 10.1002/ppul.22874.
41. Mohamed AF, Reed Johnson FR, Balp MM, et al. Convenience and stated adherence for antibiotic treatment of cystic-fibrosis pseudomonas infections [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17-19 Oct 2013; Salt Lake City.
42. Fernandez-Olmos A, Garcia-Castillo M, Maiz L, et al. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. Int J Antimicrob Agents. 2012;40(2):173-6.
43. Schelstraete P, Haerynck F, Van daele S, et al. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colinized by P. aeruginosa. J Cyst Fibros. 2013;12:1-8.
44. Lo D, VanDevanter DR, Flume P, et al. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Resp Med. 2011;105(Suppl 2):S9-17.
45. Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs. 2009;69(14):1903-10.
46. Van Westreenen M, Tiddens HAWM. New antimicrobial strategies in cystic fibrosis. Pediatr Drugs. 2010;12(6):343-52.
47. Anderson P. Emerging therapies in cystic fibrosis. Ther Adv Respir Dis. 2010;4(3):177-85.